Alterations in Phospholipase D During the Development of Myocardial Disease

Chapter
Part of the Advances in Biochemistry in Health and Disease book series (ABHD, volume 10)

Abstract

Phospholipase D (PLD) produces phosphatidic acid, which is converted to diacylglycerol (DAG) by phosphatidate phosphohydrolase (PAP). Since both these lipid signaling molecules regulate Ca2+-movements, they also influence cardiac contractile function. In this article, we discuss the importance of PLD in relation to the production of lipid signaling molecules and regulation of cardiac function under various pathophysiological conditions such as ischemic heart disease, diabetic cardiomyopathy, and congestive heart failure. In fact, marked alterations in PLD activities have been reported to occur in ischemic heart, diabetic heart, and failing heart. While the mechanisms of changes in PLD activities in heart disease may be of complex nature, oxidative stress seems to play a critical role in the activation of PLD. From the evidence provided it is suggested that impairment in this phospholipid signal transduction pathway results in cardiac dysfunction during the development of different myocardial diseases.

Keywords

Phospholipase D Signal transduction Diabetic cardiomyopathy Congestive heart failure Ischemia-reperfusion injury PLD-mediated signal transduction 

Notes

Acknowledgment

Infrastructural support was provided by the St. Boniface Hospital Research Foundation.

References

  1. 1.
    Exton JH (1994) Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1212:26–42PubMedGoogle Scholar
  2. 2.
    Panagia V, Ou C, Taira Y et al (1991) Phospholipase D activity in subcellular membranes of rat ventricular myocardium. Biochim Biophys Acta 1064:242–250PubMedGoogle Scholar
  3. 3.
    Sadoshima J, Izumo S (1993) Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 73:424–438PubMedGoogle Scholar
  4. 4.
    Ye H, Wolf RA, Kurz T, Corr PB (1994) Phosphatidic acid increases in response to noradrenaline and endothelin-1 in adult rabbit ventricular myocytes. Cardiovasc Res 28:1828–1834PubMedGoogle Scholar
  5. 5.
    Dhalla NS, Xu YJ, Sheu SS et al (1997) Phosphatidic acid: a potential signal transducer for cardiac hypertrophy. J Mol Cell Cardiol 29:2865–2871PubMedGoogle Scholar
  6. 6.
    Xu YJ, Botsford MW, Panagia V, Dhalla NS (1996) Responses of heart function and intracellular free Ca2+ to phosphatidic acid in diabetic rats. Can J Cardiol 12:1092–1098PubMedGoogle Scholar
  7. 7.
    Xu YJ, Panagia V, Shao Q et al (1996) Phosphatidic acid increases intracellular free Ca2+ and cardiac contractile force. Am J Physiol Heart Circ Physiol 271:H651–H659Google Scholar
  8. 8.
    Lamers JM, Eskildsen-Helmond YE, Resink AM et al (1995) Endothelin-1-induced phospholipase C β and D and protein kinase C isoenzyme signaling leading to hypertrophy in rat cardiomyocytes. J Cardiovasc Pharmacol 26:S100–S103PubMedGoogle Scholar
  9. 9.
    Frohman MA, Morris AJ (1999) Phospholipase D structure and function. Chem Phys Lipids 98:127–140PubMedGoogle Scholar
  10. 10.
    Freyberg Z, Sweeney D, Siddhanta A et al (2001) Intracellular localization of phospholipase D1 in mammalian cells. Mol Biol Cell 12:943–955PubMedCentralPubMedGoogle Scholar
  11. 11.
    Park JB, Kim JH, Kim KY et al (2000) Cardiac phospholipase D2 localizes to sarcolemmal membranes and is inhibited by α-actinin in an ADP-ribosylation factor-reversible manner. J Biol Chem 275:21295–21301PubMedGoogle Scholar
  12. 12.
    Hiroyama M, Exton JH (2005) Localization and regulation of phospholipase D2 by ARF6. J Cell Biochem 95:149–164PubMedGoogle Scholar
  13. 13.
    Freyberg Z, Bourgoin S, Shields D (2002) Phospholipase D2 is localized to the rims of the Golgi apparatus in mammalian cells. Mol Biol Cell 13:3930–3942PubMedCentralPubMedGoogle Scholar
  14. 14.
    Moon C, Kim H, Kim S et al (2008) Transient expression of Phospholipase D1 during heart development in rats. J Vet Med Sci 70:411–413PubMedGoogle Scholar
  15. 15.
    Hammond SM, Jenco JM, Nakashima S et al (1997) Characterization of two alternately spliced forms of phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-α. J Biol Chem 272:3860–3868PubMedGoogle Scholar
  16. 16.
    Kim JH, Lee SD, Han JM et al (1998) Activation of phospholipase D1 by direct interaction with ADP-ribosylation factor 1 and RalA. FEBS Lett 430:231–235PubMedGoogle Scholar
  17. 17.
    Lee TG, Park JB, Lee SD et al (1997) Phorbol myristate acetate-dependent association of protein kinase C α with phospholipase D1 in intact cells. Biochim Biophys Acta 1347:199–204PubMedGoogle Scholar
  18. 18.
    Liscovitch M, Chalifa V, Pertile P et al (1994) Novel function of phosphatidylinositol 4,5-bisphosphate as a cofactor for brain membrane phospholipase D. J Biol Chem 269:21403–21406PubMedGoogle Scholar
  19. 19.
    Malcolm KC, Elliott CM, Exton JH (1996) Evidence for Rho-mediated agonist stimulation of phospholipase D in rat fibroblasts. Effects of Clostridium botulinum C3 exoenzyme. J Biol Chem 271:13135–13139PubMedGoogle Scholar
  20. 20.
    Yamazaki M, Zhang Y, Watanabe H et al (1999) Interaction of the small G protein RhoA with the C terminus of human phospholipase D1. J Biol Chem 274:6035–6038PubMedGoogle Scholar
  21. 21.
    Nataranjan V, Scribner WM, Vepa S (1996) Regulation of phospholipase D by tyrosine kinases. Chem Phys Lipids 24:103–116Google Scholar
  22. 22.
    Exton JH (1998) Phospholipase D. Biochim Biophys Acta 1436:105–115PubMedGoogle Scholar
  23. 23.
    Singer WD, Brown HA, Jiang X, Sternweis PC (1996) Regulation of phospholipase D by protein kinase C is synergistic with ADP-ribosylation factor and independent of protein kinase activity. J Biol Chem 271:4504–4510PubMedGoogle Scholar
  24. 24.
    Sciorra VA, Hammond SM, Morris AJ (2001) Potent direct inhibition of mammalian phospholipase D isoenzymes by calphostin-c. Biochemistry 40:2640–2646PubMedGoogle Scholar
  25. 25.
    Hammond SM, Altshuller YM, Sung TC et al (1995) Human ADP-ribosylation factor-activated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family. J Biol Chem 270:29640–29643PubMedGoogle Scholar
  26. 26.
    Dai J, Williams SA, Ziegelhoffer A, Panagia V (1995) Structure-activity relationship of the effect of cis-unsaturated fatty acids on heart sarcolemmal phospholipase D activity. Prostagland Leuk Essent Fatty Acids 52:167–171Google Scholar
  27. 27.
    Colley WC, Sung TC, Roll R et al (1997) Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr Biol 7:191–201PubMedGoogle Scholar
  28. 28.
    Morris AJ (2007) Regulation of phospholipase D activity, membrane targeting and intracellular trafficking by phosphoinositides. Biochem Soc Symp 74:247–257PubMedGoogle Scholar
  29. 29.
    Gustavsson L, Moehren G, Torres-Marquez ME et al (1994) The role of cytosolic Ca2+, protein kinase C, and protein kinase A in hormonal stimulation of phospholipase D in rat hepatocytes. J Biol Chem 269:849–859PubMedGoogle Scholar
  30. 30.
    Kanaho Y, Nishida A, Nozawa Y (1992) Calcium rather than protein kinase C is the major factor to activate phospholipase D in FMLP-stimulated rabbit peritoneal neutrophils. Possible involvement of calmodulin/myosin L chain kinase pathway. J Immunol 149:622–628PubMedGoogle Scholar
  31. 31.
    Kiss Z (1992) Differential effects of platelet-derived growth factor, serum and bombesin on phospholipase D-mediated hydrolysis of phosphatidylethanolamine in NIH 3T3 fibroblasts. Biochem J 285:229–233PubMedCentralPubMedGoogle Scholar
  32. 32.
    Kurose H (2003) Gα12 and Gα13 as key regulatory mediator in signal transduction. Life Sci 74:155–161PubMedGoogle Scholar
  33. 33.
    Lopez I, Arnold RS, Lambeth JD (1998) Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2. J Biol Chem 273:12846–12852PubMedGoogle Scholar
  34. 34.
    Dascher C, Balch WE (1994) Dominant inhibitory mutants of ARF1 block endoplasmic reticulum to Golgi transport and trigger disassembly of the Golgi apparatus. J Biol Chem 269:1437–1448PubMedGoogle Scholar
  35. 35.
    Rumenapp U, Geiszt M, Wahn F et al (1995) Evidence for ADP-ribosylation-factor-mediated activation of phospholipase D by m3 muscarinic acetylcholine receptor. Eur J Biochem 234:240–244PubMedGoogle Scholar
  36. 36.
    Shome K, Nie Y, Romero G (1998) ADP-ribosylation factor proteins mediate agonist-induced activation of phospholipase D. J Biol Chem 273:30836–30841PubMedGoogle Scholar
  37. 37.
    Burgdorf C, Schafer U, Richardt G, Kurz T (2010) U73122, an aminosteroid Phospholipase C inhibitor, is a potent inhibitor of cardiac Phospholipase D by PIP2-dependent mechanism. J Cardiovasc Pharmacol 55:555–559PubMedGoogle Scholar
  38. 38.
    Kukreja RC, Hess ML (1992) The oxygen free radical system: from equations through membrane-protein interactions to cardiovascular injury and protection. Cardiovasc Res 26:641–655PubMedGoogle Scholar
  39. 39.
    Singal PK, Khaper N, Palace V, Kumar D (1998) The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 40:426–432PubMedGoogle Scholar
  40. 40.
    Müller BA, Dhalla NS (2010) Mechanisms of the beneficial actions of ischemic preconditioning on subcellular remodeling in ischemic-reperfused heart. Curr Cardiol Rev 6:255–264PubMedCentralPubMedGoogle Scholar
  41. 41.
    Dhalla NS, Liu X, Panagia V, Takeda N (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40:239–247PubMedGoogle Scholar
  42. 42.
    Mullarkey CJ, Edelstein D, Brownlee M (1990) Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173:932–939PubMedGoogle Scholar
  43. 43.
    Giugliano D, Marfella R, Acampora R et al (1998) Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 21:631–636PubMedGoogle Scholar
  44. 44.
    Jain SK, McVie R, Jaramillo JJ et al (1996) The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids 31(suppl):S87–S90PubMedGoogle Scholar
  45. 45.
    Dhalla NS, Pierce GN, Innes IR, Beamish RE (1985) Pathogenesis of cardiac dysfunction in diabetes mellitus. Can J Cardiol 1:263–281PubMedGoogle Scholar
  46. 46.
    Afzal N, Ganguly PK, Dhalla KS et al (1988) Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37:936–942PubMedGoogle Scholar
  47. 47.
    Golfman L, Dixon IMC, Takeda N et al (1998) Cardiac sarcolemmal Na+-Ca2+ exchange and Na+-K+ ATPase activities and gene expression in alloxan-induced diabetes in rats. Mol Cell Biochem 188:91–101PubMedGoogle Scholar
  48. 48.
    Williams SA, Tappia PS, Yu CH et al (1997) Subcellular alterations in cardiac phospholipase D activity in chronic diabetes. Prostagland Leuk Essent Fatty Acids 57:95–99Google Scholar
  49. 49.
    Williams SA, Tappia PS, Yu CH et al (1998) Impairment of the sarcolemmal phospholipase D-phosphatidate phosphohydrolase pathway in diabetic cardiomyopathy. J Mol Cell Cardiol 30:109–118PubMedGoogle Scholar
  50. 50.
    Dzau VJ (2001) Tissue angiotensin and pathobiology of vascular disease. Hypertension 37:1047–1052PubMedGoogle Scholar
  51. 51.
    Privratsky JR, Wold LE, Sowers JR et al (2003) AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42:206–212PubMedGoogle Scholar
  52. 52.
    Ortmeyer J, Mohsenin V (1996) Inhibition of phospholipase D and superoxide generation by glucose in diabetic neutrophils. Life Sci 59:255–262PubMedGoogle Scholar
  53. 53.
    Tappia PS, Liu SY, Tong Y et al (2001) Reduction of phosphatidylinositol-4,5-bisphosphate mass in heart sarcolemma during diabetic cardiomyopathy. Adv Exp Med Biol 498:183–190PubMedGoogle Scholar
  54. 54.
    Mesaeli N, Tappia PS, Suzuki S et al (2000) Oxidants depress the synthesis of phosphatidylinositol 4,5-bisphosphate in heart sarcolemma. Arch Biochem Biophys 382:48–56PubMedGoogle Scholar
  55. 55.
    Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655–673PubMedGoogle Scholar
  56. 56.
    Dhalla NS, Golfman L, Takeda S et al (1999) Evidence for the role of oxidative stress in acute ischemic heart disease: a brief review. Can J Cardiol 15:587–593PubMedGoogle Scholar
  57. 57.
    Dhalla NS, Temsah R (2001) Sarcoplasmic reticulum and cardiac oxidative stress: an emerging target for heart disease. Expert Opin Ther Targets 5:205–217PubMedGoogle Scholar
  58. 58.
    Giordano FJ (2005) Oxygen, oxidative stress, hypoxia and heart failure. J Clin Invest 115:500–508PubMedCentralPubMedGoogle Scholar
  59. 59.
    Kaneko M, Elimban V, Dhalla NS (1989) Mechanism for depression of heart sarcolemmal Ca2+ pump by oxygen free radicals. Am J Physiol Heart Circ Physiol 257:H804–H811Google Scholar
  60. 60.
    Kaneko M, Beamish RE, Dhalla NS (1989) Depression of heart sarcolemmal Ca2+-pump activity by oxygen free radicals. Am J Physiol Heart Circ Physiol 256:H368–H374Google Scholar
  61. 61.
    Kaneko M, Lee SL, Wolf CM, Dhalla NS (1989) Reduction of calcium channel antagonist binding sites by oxygen free radicals in rat heart. J Mol Cell Cardiol 21:935–943PubMedGoogle Scholar
  62. 62.
    Kaneko M, Chapman DC, Ganguly PK et al (1991) Modification of cardiac adrenergic receptors by oxygen free radicals. Am J Physiol Heart Circ Physiol 260:H821–H826Google Scholar
  63. 63.
    Okabe E, Hess ML, Oyama M, Ito H (1983) Characterization of free radical-mediated damage of canine cardiac sarcoplasmic reticulum. Arch Biochem Biophys 225:164–177PubMedGoogle Scholar
  64. 64.
    Otani H, Tanaka H, Inoue T et al (1984) In vitro study on contribution of oxidative metabolism of isolated rabbit heart mitochondria to myocardial reperfusion injury. Circ Res 55:168–175PubMedGoogle Scholar
  65. 65.
    Peivandi AA, Huhn A, Lehr HA et al (2005) Upregulation of phospholipase D expression and activation in ventricular pressure-overload hypertrophy. J Pharmacol Sci 98:244–254PubMedGoogle Scholar
  66. 66.
    Yamamoto K, Takahashi Y, Mano T et al (2004) N-methylethanolamine attenuates cardiac fibrosis and improves diastolic function: inhibition of Phospholipase D as a possible mechanism. Eur Heart J 25:1221–1229PubMedGoogle Scholar
  67. 67.
    Dent MR, Singal T, Dhalla NS, Tappia PS (2005) Expression of phospholipase D isozymes in scar and viable tissue in congestive heart failure due to myocardial infarction. J Cell Mol Med 8:526–536Google Scholar
  68. 68.
    Kasai T, Ohguchi K, Nakashima S et al (1998) Increased activity of oleate-dependent type phospholipase D during actinomycin D-induced apoptosis in Jurkat T cells. J Immunol 161:6469–6474PubMedGoogle Scholar
  69. 69.
    Yamakawa H, Banno Y, Nakashima S et al (2000) Increased phospholipase D2 activity during hypoxia-induced death of PC12 cells: its possible anti-apoptotic role. Neuroreport 11:3647–3650PubMedGoogle Scholar
  70. 70.
    Tojo A, Onozato ML, Kobayashi N et al (2002) Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 40:834–839PubMedGoogle Scholar
  71. 71.
    Harrison DG, Cai H, Landmesser U, Griendling KK (2003) Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4:51–61PubMedGoogle Scholar
  72. 72.
    Dhalla NS, Shao Q, Panagia V (1998) Remodeling of cardiac membranes during the development of congestive heart failure. Heart Fail Rev 2:261–272Google Scholar
  73. 73.
    Heymes C, Bendall JK, Ratajczak P et al (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164–2171PubMedGoogle Scholar
  74. 74.
    Li JM, Gall NP, Grieve DJ et al (2002) Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40:477–484PubMedGoogle Scholar
  75. 75.
    Yu CH, Panagia V, Tappia PS et al (2002) Alterations of sarcolemmal phospholipase D and phosphatidate phosphohydrolase in congestive heart failure. Biochim Biophys Acta 1584:65–72PubMedGoogle Scholar
  76. 76.
    Kloner RA, Ellis SG, Lange R, Braunwald E (1983) Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation 68:I8–I15PubMedGoogle Scholar
  77. 77.
    Freeman BA, Crapo JD (1982) Biology of disease: free radicals and tissue injury. Lab Invest 47:412–426PubMedGoogle Scholar
  78. 78.
    Ferrari R, Alfieri O, Curello S et al (1990) Occurrence of oxidative stress during reperfusion of the human heart. Circulation 81:201–211PubMedGoogle Scholar
  79. 79.
    Hasenfuss G, Meyer M, Schillinger W (1997) Calcium handling proteins in the failing human heart. Basic Res Cardiol 92:87–93PubMedGoogle Scholar
  80. 80.
    Palace V, Kumar D, Hill MF, Khaper N, Singal PK (1999) Regional differences in non-enzymatic antioxidants in the heart under control and oxidative stress conditions. J Mol Cell Cardiol 31:193–202PubMedGoogle Scholar
  81. 81.
    Meerson FZ, Kagan VE, Kozlov Yu P et al (1982) The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. Basic Res Cardiol 77:465–485PubMedGoogle Scholar
  82. 82.
    Natarajan V, Scribner VM, Hart CM, Parthasarathy S (1995) Oxidized low density lipoprotein-mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis. J Lipid Res 36:2005–2016PubMedGoogle Scholar
  83. 83.
    Goel DP, Vecchini A, Panagia V, Pierce GN (2000) Altered cardiac Na+/H+ exchange in Phospholipase D-treated sarcolemmal vesicles. Am J Physiol Heart Circ Physiol 279:H1179–H1184PubMedGoogle Scholar
  84. 84.
    Tosaki A, Maulik N, Cordis G et al (1997) Ischemic preconditioning triggers phospholipase D signaling in rat heart. Am J Physiol Heart Circ Physiol 273:H1860–H1866Google Scholar
  85. 85.
    Bruhl A, Faldum A, Loffelholz K (2003) Degradation of phosphatidylethanol counteracts the apparent phospholipase D-mediated formation in heart and other organs. Biochim Biophys Acta 1633:84–89PubMedGoogle Scholar
  86. 86.
    Bruhl A, Hafner G, Loffelholz K (2004) Release of choline in the isolated heart, an indicator of ischemic phospholipid degradation and its protection by ischemic preconditioning: no evidence for a role of phospholipase D. Life Sci 75:1609–1620PubMedGoogle Scholar
  87. 87.
    Kurz T, Kemken D, Mier K et al (2004) Human cardiac phospholipase D activity is tightly controlled by phosphatidylinositol 4,5-bisphosphate. J Mol Cell Cardiol 36:225–232PubMedGoogle Scholar
  88. 88.
    Asemu G, Dent MR, Singal T et al (2005) Differential changes in phospholipase D and phosphatidate phosphohydrolase activities in ischemia-reperfusion of rat heart. Arch Biochem Biophys 436:136–144PubMedGoogle Scholar
  89. 89.
    Liu SY, Tappia PS, Dai J et al (1998) Phospholipase A2-mediated activation of phospholipase D in rat heart sarcolemma. J Mol Cell Cardiol 30:1203–1214PubMedGoogle Scholar
  90. 90.
    Sapirstein A, Spech RA, Witzgall R, Bonventre JV (1996) Cytosolic phospholipase A2 (PLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells. J Biol Chem 271:21505–21513PubMedGoogle Scholar
  91. 91.
    Ferrari R, Ceconni C, Curello S et al (1991) Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am J Med 91:95S–105SPubMedGoogle Scholar
  92. 92.
    Gilbert HF (1984) Redox control of enzyme activities by thiol/disulfide exchange. Methods Enzymol 107:330–351PubMedGoogle Scholar
  93. 93.
    Moraru II, Popescu LM, Maulik N et al (1992) Phospholipase D signaling in ischemic heart. Biochim Biophys Acta 1139:148–154PubMedGoogle Scholar
  94. 94.
    Cohen MV, Liu Y, Liu GS et al (1996) Phospholipase D plays a role in ischemic preconditioning in rabbit heart. Circulation 94:1713–1718PubMedGoogle Scholar
  95. 95.
    Trifan OC, Popescu LM, Tosaki A et al (1996) Ischemic preconditioning involves phospholipase D. Ann NY Acad Sci 793:485–488PubMedGoogle Scholar
  96. 96.
    Lecour S, Rochette L, Opie L (2005) TNFα-induced cardioprotection. Cardiovasc Res 65:239–243PubMedGoogle Scholar
  97. 97.
    Tritto I, Ambrosio G (2001) Role of oxidants in the signaling pathway of preconditioning. Antioxid Redox Signal 3:3–10PubMedGoogle Scholar
  98. 98.
    Armstrong SC (2004) Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 61:427–436PubMedGoogle Scholar
  99. 99.
    Eskildsen-Helmond YE, Gho BC, Bezstarosti K et al (1998) Exploration of the possible roles of phospholipase D and protein kinase C in the mechanism of ischemic preconditioning in the myocardium. Ann NY Acad Sci 793:210–225Google Scholar
  100. 100.
    Tappia PS (2007) Phospholipid-mediated signaling systems as novel targets for treatment of heart disease. Can J Physiol Pharmacol 85:25–41PubMedGoogle Scholar
  101. 101.
    Tappia PS, Singal T (2008) Phospholipid-mediated signaling and heart disease. Subcell Biochem 49:299–324PubMedGoogle Scholar
  102. 102.
    Tappia PS, Dent MR, Dhalla NS (2008) Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med 41:349–361Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Asper Clinical Research InstituteSt. Boniface Hospital Research CentreWinnipegCanada
  2. 2.Faculty of Medicine, Institute of Cardiovascular Sciences and Department of PhysiologyUniversity of ManitobaWinnipegCanada

Personalised recommendations